Latest news with #ATMP
Barnama
2 days ago
- Business
- Barnama
KESUMA, Penang To Partner On Talent Pipeline For Chip Design, High-tech Sectors
GEORGE TOWN, June 19 (Bernama) -- The Human Resources Ministry (KESUMA) is finalising a strategic collaboration with the Penang government to strengthen the local talent pipeline by producing more engineers through the Penang Chip Design Academy (PCDA). Human Resources Minister Steven Sim Chee Keong said the academy, established by the state government, is aimed at advancing Penang's semiconductor and high-tech sectors, with KESUMA poised to add value to the initiative. 'PCDA was created to develop human capital, young people and workers, for the semiconductor and high-tech industries. 'KESUMA wants to explore how we can support the state's skill training programmes to drive this sector forward,' he told reporters after launching the National Training Week (NTW) 2025 Northern Region roadshow here today. Penang launched the academy last year as part of efforts to strengthen integrated circuit (IC) design and digital development, aligning with the state's plans to build a thriving IC design ecosystem and digital economy hub. Sim also announced a strategic partnership between the Human Resource Development Corporation (HRD Corp) and the Northern Corridor Implementation Authority (NCIA) under the Advanced Technology Meister Programme (ATMP). 'Through this initiative, we are introducing a matching grant programme to help local industries enhance workforce skills in advanced technology,' he said. Employers will be able to co-develop training programmes with learning institutions of their choice, supported by funding from both HRD Corp via its levy system, as well as NCIA under the 12th Malaysia Plan (RMK12). Sims aid the initiative reflects the government's commitment to building a highly skilled workforce and achieving the national target of 30 per cent skilled labour by 2030.
The Sun
2 days ago
- Business
- The Sun
KESUMA, Penang to partner on talent pipeline for chip design, high-tech sectors
GEORGE TOWN: The Human Resources Ministry (KESUMA) is finalising a strategic collaboration with the Penang government to strengthen the local talent pipeline by producing more engineers through the Penang Chip Design Academy (PCDA). Human Resources Minister Steven Sim Chee Keong said the academy, established by the state government, is aimed at advancing Penang's semiconductor and high-tech sectors, with KESUMA poised to add value to the initiative. 'PCDA was created to develop human capital, young people and workers, for the semiconductor and high-tech industries. 'KESUMA wants to explore how we can support the state's skill training programmes to drive this sector forward,' he told reporters after launching the National Training Week (NTW) 2025 Northern Region roadshow here today. Penang launched the academy last year as part of efforts to strengthen integrated circuit (IC) design and digital development, aligning with the state's plans to build a thriving IC design ecosystem and digital economy hub. Sim also announced a strategic partnership between the Human Resource Development Corporation (HRD Corp) and the Northern Corridor Implementation Authority (NCIA) under the Advanced Technology Meister Programme (ATMP). 'Through this initiative, we are introducing a matching grant programme to help local industries enhance workforce skills in advanced technology,' he said. Employers will be able to co-develop training programmes with learning institutions of their choice, supported by funding from both HRD Corp via its levy system, as well as NCIA under the 12th Malaysia Plan (RMK12). Sims aid the initiative reflects the government's commitment to building a highly skilled workforce and achieving the national target of 30 per cent skilled labour by 2030. In a separate announcement, KESUMA also approved the implementation of a skills enhancement programme under the Focused Impact Training Initiative (FITI) for fishing families and local communities in South Penang. The programme will benefit 420 participants through courses such as helmsman training, site safety supervision, computer applications and safety officer certification. 'The goal is to ensure that the fishing community is not left behind in economic progress brought by projects such as Silicon Island,' Sim said.
Yahoo
4 days ago
- Business
- Yahoo
King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
Unveiled at BIO 2025 in Boston, the project marks a major step toward Saudi Arabia's goal to become a global biotechnology hub by 2040. BOSTON, June 17, 2025 /PRNewswire/ -- BIO International Convention 2025 -- At the BIO International Convention 2025 in Boston, King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. The new facility will be located at KFSHRC's main campus in Riyadh and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at transforming the Kingdom into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040. "This initiative marks a historic milestone, not just for our institution, but for the Kingdom of Saudi Arabia in alignment with Vision 2030 and the National Biotechnology Strategy," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "With Germfree as our partner, we are creating a world-class advanced therapies campus that will accelerate access to transformative treatments, draw the brightest minds in science, and strengthen Saudi Arabia's position as a global leader in biotechnology. This fast-track, strategic project represents a continuation of the long history of healthcare innovation that has been realized by King Faisal Specialist Hospital and Research Centre." "KFSHRC's leadership and vision align with Germfree's mission to expand access to complex therapies through future-proofed, agile infrastructure," said Kevin Kyle, CEO of Germfree Laboratories. "Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we're building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi Arabia, the Middle East, and beyond. This collaboration reflects the critical role infrastructure plays in unlocking access to advanced therapies, and we are proud to support KFSHRC's vision for patient-centric care." Under the terms of a signed Letter of Intent, the turnkey project will fast-track the Kingdom's ability to manufacture cell and gene therapies locally, host international clinical trials, and attract leading pharmaceutical partnerships and scientific talent from around the world. Driving Saudi Arabia's Vision for Global Biotech Leadership This project directly supports Saudi Arabia's National Biotechnology Strategy, launched to localize vaccine and therapeutic production, develop sovereign biomanufacturing capabilities, and establish the Kingdom as a global biotechnology leader by 2040. As a core pillar of Vision 2030, the strategy aims to make Saudi Arabia a destination for clinical trials, scientific discovery, pharmaceutical investment, and biotech entrepreneurship across the Middle East and beyond. By establishing a globally competitive manufacturing campus, KFSHRC is not only advancing national healthcare; it is setting a new global standard for innovation, scalability, and patient-centered care. A Smart, Scalable Biomanufacturing Platform The ATMP Manufacturing Campus will be delivered as a fully CGMP-compliant, off-site built, modular solution, developed in strategic phases to support immediate clinical impact and long-term growth. The project will begin with the deployment of Germfree's BioGO® Box single-module cleanroom solution, enabling early operator training, tech transfer, and R&D activities. In parallel, a newly constructed facility will be built centrally on the KFSHRC campus to house prefabricated modular cleanroom clusters, providing 16 production suites, each designed for multi-modal CGT production supporting both clinical and commercial-scale manufacturing. Full operational readiness will be reached just 18 months after contract signing, roughly half the timeline of a conventional stick-built facility of comparable scope. That speed, combined with the flexibility to scale or repurpose suites as new therapies emerge, means Saudi patients will gain access to advanced treatments years sooner than traditional construction would allow. The state-of-the-art facility will meet SFDA, FDA, EMA, and BMBL requirements and will include a fully integrated digital manufacturing platform designed to support smart, data-driven CGMP operations from day one. Germfree's continued growth is supported by EW Healthcare Partners, a leading private equity company that makes growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe. About King Faisal Specialist Hospital & Research Centre (KFSHRC) King Faisal Specialist Hospital & Research Centre is Saudi Arabia's foremost tertiary-and-quaternary referral institution, delivering world-class care in oncology, transplantation, cardiovascular medicine and precision therapeutics. It is ranked No. 1 in the Middle East & Africa and 15th globally among academic medical centers by Brand Finance's 2025 report and is listed on Newsweek's World's Best Hospitals as well as World's Best Smart Hospitals 2025. As a flagship partner in the Kingdom's Vision 2030 and National Biotechnology Strategy an initiative to localize biomanufacturing and make Saudi Arabia a global biotech hub by 2040, KFSHRC forges international collaborations, drives cutting-edge clinical research, and cultivates Saudi scientific talent to expand patient access to life-changing therapies. About Germfree Laboratories Germfree advances ATMP development and point-of-care manufacturing by delivering U.S-designed and built, ready-to-operate modular and mobile CGMP cleanrooms, integrated equipment, and lifecycle services under a single contract. Today, more than 200 Germfree laboratories, cleanrooms, and complex equipment systems operate in 32 countries, underscoring the company's commitment to innovative, agile, integrated, and impactful research and biomanufacturing worldwide. Strategic partnerships with process-technology leaders and in-country service firms ensure every deployment arrives fully validated, operationally ready, and regulatory compliant from day one. The company's U.S. manufacturing hub and on-site service programs ensure rapid deployment, sustained performance, knowledge transfer to local workforces and a continuous pipeline of innovation that keeps facilities future ready as advanced therapies evolve. View original content to download multimedia: SOURCE Germfree Laboratories LLC Sign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
A Decade of Cell & Gene Therapy Manufacturing and Major GMP Facility Expansion: Cellex's Track Record of Scalable Excellence
Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe. COLOGNE, Germany, June 10, 2025 /PRNewswire/ -- Cellex Cell Professionals (Cellex), a full-service Contract Development and Manufacturing Organization (CDMO) with 10+ years of experience in Cell & Gene Therapy (CGT), announces facility expansion and reflects on a series of milestones that have shaped its position as a trusted partner in CGT/ATMP manufacturing. With strategic facility expansions, groundbreaking collaborations, and a proven clinical and commercial record of accomplishment, the company continues to solidify its leadership within the European CGT sector. A Legacy Built on Purpose and Growth Founded in 2001 in Dresden by Prof. Dr. Gerhard Ehninger to secure sourcing of cellular therapies for patients in need of an allogeneic blood stem cell transplantation, Cellex has grown into one of Europe's leading CGT CDMOs, driven by a strong focus on patient access and operational excellence. In 2009, Cellex expanded to Cologne by opening a second collection center. Since then, the team performed over 50,000 cell collections. By 2013, the company extended its services to cover the entire value chain, ensuring reliable global transport of more than 20,000 cellular shipments to date - further establishing its end-to-end manufacturing capability. Since 2018, Cellex has supported the CGT supply chain with a donor database for R&D, clinical trials, and commercial programs, supplying GMP-grade starting materials such as Leukopaks, Mobilized Leukopaks, Whole Blood, and Bone Marrow. Cellex Announces Major Facility Expansion and Operational Milestones From 2019 onward, Cellex undertook three major expansions of its GMP infrastructure, integrating high-throughput cleanroom environments and quality control labs. With the latest facility expansion, the company operates over 2,500 m² (over 27,000 ft²) of GMP-certified manufacturing area, with 43% allocated to cleanroom operations across 37 workstations. With more than 5,800 CGT/ATMP batches manufactured - including 1,300+ clinical and 4,500+ commercial products - Cellex has demonstrated consistent execution across the full development spectrum. The company currently manufactures six final drug products and seven cellular intermediates, and supports the commercial production of three CAR-T therapies approved in the EU. In 2023, Cellex successfully manufactured Europe's first allogeneic CAR-T product, reinforcing its role in cutting-edge therapy development. "In the manufacturing of advanced therapies, innovation must be matched by a high degree of precision and reliability." says Carla Kreissig, Managing Director and Chief Medical Officer of Cellex. "Reaching over 5,800 batches reflects not just scale - but deep process maturity and trust from our partners. With our latest GMP facility expansion, we are further strengthening our capabilities to meet growing demand and ensure continued excellence." Additionally, a new materials warehouse was launched this year. Designed to the highest standards, it ensures quality, safety, and efficiency for every batch. With expanded storage capacity, we are well equipped to meet the continuously growing demand in CGT manufacturing. From Early Innovation to Scalable CGT Manufacturing In 2014, Cellex entered the CGT field by launching its first preclinical and clinical development program focused on adapter CAR-T technology in Dresden. A dedicated manufacturing facility was established in Cologne to support PoC trials for academic and biotech partners. Long-standing partnerships underscore the company's credibility and manufacturing maturity: A collaboration with the first pharma client began in 2017, with the first commercial batch delivered in 2023. Work with the next pharma client started in 2020, followed by the first commercial delivery in 2024. Looking Ahead: Growth, Pipeline, and Commitment In January 2025, Cellex Cell Professionals onboarded two new clients, with a robust pipeline of new mandates for the remainder of the year and beyond. With over 10 years of experience in autologous and allogeneic cell therapy and the ability to support clients from preclinical phases through to commercial launch, Cellex Cell Professionals remains uniquely positioned among European CDMOs - defined not by capability alone, but by a proven record of execution. About Cellex Cell Professionals Cellex Cell Professionals is a leading, full service CDMO specializing in CGT. With its state-of-the-art facilities located in Cologne, Germany, and a proven track record of 10+ years in GMP-compliant autologous and allogeneic cell therapy manufacturing, Cellex is partnered with several major pharma and innovative biotech companies supporting their process development and clinical and commercial manufacturing. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as storage and logistics services. Learn more at Media ContactPhone: +49 221 2509 0E-mail: infocenter@ Logo: View original content to download multimedia: SOURCE Cellex Cell Professionals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
03-06-2025
- Business
- Time of India
Tata Electronics eyes Malaysia foray via chip fab acquisition
Tata Electronics is in talks with several global semiconductor companies including X-Fab , DNeX and Globetronics to acquire a fabrication or outsourced semiconductor assembly and test (OSAT) plant in Malaysia, according to people in the know. The move is aimed at bolstering the Tata Group company's knowledge and talent base before entering the semiconductor assembly and packaging business in India. KC Ang, who was appointed president and head of Tata Semiconductor Manufacturing in April this year, is driving these acquisition efforts, the people said. 'Globetronics and DNeX's SilTerra facility are among the front runners to be acquired by Tata Electronics,' said one of the people. Tata Electronics is investing more than Rs 91,000 crore to set up a semiconductor fab unit at Dholera, Gujarat, and Rs 27,000 crore in an OSAT facility at Assam's Morigaon. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký "Running a fab is not going to be simple and Tata Electronics is aware of that," a second person said. ETtech Live Events "These potential acquisitions are being explored in Malaysia because it is one of the most economical options and talks have been going on with different players since April this year,' this person said. 'For the Tatas, it represents an opportunity to get the knowhow on how to run a fab or advanced packaging facility while also providing a training ground for Indian talent to learn how to run these high-tech facilities." Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories Queries sent to Tata Electronics, X-Fab, DNeX and Globetronics remained unanswered as of press time Monday. Semicon hub Malaysia's expertise in assembly, testing, marking and packaging (ATMP) along with its mature ecosystem, abundant skilled workforce, robust supply chain and government support make it a preferred destination, according to analysts. "If Tata were to have a partnership or presence in Malaysia, it would enable Tata to develop expertise in ATMP, and it would complement the wafer fabrication and OSAT (operations) in India," Counterpoint Research senior analyst Parv Sharma said. 'It would also de-risk Tata from current semiconductor tariffs and provide a risk-free supply chain to serve a wider customer base globally," he added. Also, the Malaysian government's National Semiconductor Strategy, announced in May 2024, offers a significant incentive structure to attract investments. Indian companies are aiming to acquire manufacturing grade technology (MGT) from Malaysia for OSAT projects in particular, as it is the longstanding hub for both legacy and advanced packaging. "MGT can only come from an established player in the semiconductor industry who has IP defensibility for its technology and has the legal rights to license it to India," consultancy firm Fab Economics' CEO Danish Faruqui said. Malaysia holds 13% of the global market for chip packaging, assembly and testing services, as per a February 18 report by the Malaysian Investment Development Authority. Ripe for acquisition Typically, semiconductor businesses that are financially stressed and are looking to get a boost by licensing technology and/or expanding packaging capacity with new partners, are the most preferred targets by Indian players. "Globetronics, an OSAT player from Penang, Malaysia, has suffered multiple financial blows as recently as in 2024,' said Faruqui. Key public and private stakeholders had rolled back their positions in the company, necessitating boardroom changes and strategies for new partnerships and revenue streams, he added. As per Fab Economics, DNeX's SilTerra facility in Kulim is also being deemed a 'lucrative target' for Indian players for low-cost, high-fidelity technology licensing on the fabrication side. SilTerra is a semiconductor wafer foundry offering fabrication and design support services for integrated chips in various technologies. DNeX acquired a 60% stake in SilTerra in 2021 while the remaining 40% was acquired by Beijing-based Integrated Circuit Advanced Manufacturing and High-End Equipment Equity Investment Fund Centre (CGP Fund), which is a Chinese investment fund focused on the semiconductor industry. The total acquisition cost was 273 million Malaysian ringgit (about $64 million now). X-Fab is a German specialty foundry group that has six wafer fabs located in Malaysia, Germany, France and the US. Located in Kuching, the capital city of Sarawak, the X-Fab facility in Malaysia manufactures wafers on modular CMOS technologies in geometries ranging from 350 nm to 180 nm. CMOS (Complementary Metal-Oxide-Semiconductor) is a type of technology used in computer processors, memory chips, and other electronic components.
